BridgeBio Pharma, Inc. vs Abbvie Inc.
BBIO vs ABBV — side-by-side comparison from reported financials. BBIO leads 2, ABBV leads 7 of 9 comparable metrics.
BridgeBio Pharma, Inc.
BBIO · Healthcare
$65.35+0.48%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | BBIO | ABBV |
|---|---|---|
| Price | $65.35 | $276.43 |
| Market cap | $12.8B | $488B |
| Revenue (TTM) | $713M | $64.4B |
| Revenue growth | +86.3% | +1.8% |
| Net margin | -97.0% | 9.8% |
| Free cash flow | -$435M | $18.2B |
| Net cash (debt) | ($1.26B) | ($56.2B) |
| 1-year price return | +19.3% | +19.8% |
| P/E | — | 77.4 |
| P/E vs own history (cheap-side %) | — | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -207% | 96% |
| Altman Z-score | -2.72 | 2.33 |
| CV checks passed | 3 of 9 | 9 of 9 |
| Employees | 839 | 57,000 |
Full résumé-style profiles: BBIO CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.